Hasan S Jafri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8224581/publications.pdf

Version: 2024-02-01

70	5,445	81900	85541
papers	citations	39 h-index	71 g-index

72	72	72	5583
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study. Journal of Clinical Microbiology, 2022, 60, .	3.9	1
2	Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infectious Diseases, The, 2021, 21, 1313-1323.	9.1	46
3	Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. Journal of Infectious Diseases, 2018, 217, 24-34.	4.0	76
4	Characterisation of antiâ€alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin. Clinical and Translational Immunology, 2018, 7, e1009.	3.8	24
5	Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial. PLoS ONE, 2018, 13, e0193445.	2.5	17
6	Antibody-based therapy to combat Staphylococcus aureus infections. Clinical Microbiology and Infection, 2017, 23, 219-221.	6.0	14
7	New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 346-358.	2.1	11
8	Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	106
9	Alternatives to antibiotics. Intensive Care Medicine, 2016, 42, 2034-2036.	8.2	24
10	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Publicâ€“Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.. Clinical Infectious Diseases, 2016, 63, S46-S51.	5.8	19
11	Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893. Antimicrobial Agents and Chemotherapy, 2016, 60, 5312-5321.	3.2	41
12	The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European publicâ€“private partnerships for the development of new strategies to tackle antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2016, 71, 290-295.	3.0	101
13	Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1398-1408.	9.1	157
14	Characterization of Alpha-Toxin hla Gene Variants, Alpha-Toxin Expression Levels, and Levels of Antibody to Alpha-Toxin in Hemodialysis and Postsurgical Patients with Staphylococcus aureus Bacteremia. Journal of Clinical Microbiology, 2015, 53, 227-236.	3.9	42
15	Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database. BMC Health Services Research, 2015, 15, 241.	2.2	30
16	Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity. Infectious Diseases and Therapy, 2014, 3, 339-347.	4.0	4
17	Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation. Infectious Diseases and Therapy, 2014, 3, 203-214.	4.0	6
18	Distribution of Respiratory Syncytial Virus Subtypes A and B Among Infants Presenting to the Emergency Department With Lower Respiratory Tract Infection or Apnea. Pediatric Infectious Disease Journal, 2013, 32, 335-340.	2.0	55

#	Article	IF	Citations
19	A Systematic Review of Risk Factors Associated with Surgical Site Infections among Surgical Patients. PLoS ONE, 2013, 8, e83743.	2.5	290
20	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 415-420.	2.0	135
21	Caspofungin Versus Liposomal Amphotericin B. Pediatric Infectious Disease Journal, 2010, 29, 986-987.	2.0	0
22	Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants. Clinical Therapeutics, 2010, 32, 2422-2432.	2.5	18
23	Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2010, 54, 4116-4123.	3.2	121
24	A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. Pediatrics, 2009, 123, 877-884.	2.1	123
25	Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers. Antimicrobial Agents and Chemotherapy, 2009, 53, 1450-1456.	3.2	82
26	Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. Antimicrobial Agents and Chemotherapy, 2009, 53, 869-875.	3.2	131
27	Pharmacokinetics and Pharmacodynamics of Linezolid in Children With Cystic Fibrosis. Pediatric Pulmonology, 2009, 44, 148-154.	2.0	45
28	Effect of dexamethasone on respiratory syncytial virusâ€induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. Pediatric Allergy and Immunology, 2009, 20, 477-485.	2.6	40
29	SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2009, 28, 1132-1135.	2.0	36
30	Infliximab Treatment of Intravenous Immunoglobulinâ€“Resistant Kawasaki Disease. Journal of Pediatrics, 2008, 153, 833-838.e6.	1.8	260
31	MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14046-14051.	7.1	135
32	Respiratory Syncytial Virus Persistence in the Lungs Correlates with Airway Hyperreactivity in the Mouse Model. Journal of Infectious Diseases, 2008, 198, 1435-1443.	4.0	43
33	Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections. Pediatric Infectious Disease Journal, 2008, 27, 330-334.	2.0	78
34	Respiratory Syncytial Virus Persistence. Pediatric Infectious Disease Journal, 2008, 27, S60-S62.	2.0	29
35	Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses. Journal of Infectious Diseases, 2007, 195, 1126-1136.	4.0	357
36	DIAGNOSTIC VIROLOGY PRACTICES FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA VIRUS AMONG CHILDREN IN THE HOSPITAL SETTING: A NATIONAL SURVEY. Pediatric Infectious Disease Journal, 2007, 26, 956-958.	2.0	8

#	Article	IF	Citations
37	Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients. Pediatric Infectious Disease Journal, 2007, 26, 1089-1093.	2.0	100
38	SUCCESSFUL MEDICAL TREATMENT OF CUTANEOUS ASPERGILLOSIS IN A PREMATURE INFANT USING LIPOSOMAL AMPHOTERICIN B, VORICONAZOLE AND MICAFUNGIN. Pediatric Infectious Disease Journal, 2007, 26, 364-366.	2.0	56
39	Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model. Virology Journal, 2007, 4, 109.	3.4	17
40	Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2006, 97, 457-463.	1.0	65
41	A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2268-2273.	7.1	95
42	Antibiotic Therapy for Nontuberculous Mycobacterial Cervicofacial Lymphadenitis. Laryngoscope, 2005, 115, 1746-1751.	2.0	64
43	Mobilization of Plasmacytoid and Myeloid Dendritic Cells to Mucosal Sites in Children with Respiratory Syncytial Virus and Other Viral Respiratory Infections. Journal of Infectious Diseases, 2005, 191, 1105-1115.	4.0	127
44	Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency. Antimicrobial Agents and Chemotherapy, 2005, 49, 4700-4707.	3.2	99
45	Respiratory Syncytial Virus Infections: Old Challenges and New Opportunities. Pediatric Infectious Disease Journal, 2005, 24, S189-S197.	2.0	37
46	Herpes Simplex Virus Encephalitis During Suppressive Therapy With Acyclovir in a Premature Infant. Pediatrics, 2005, 115, 804-809.	2.1	44
47	Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virology Journal, 2005, 2, 46.	3.4	45
48	Respiratory Syncytial Virus: Old Challenges and New Approaches. Pediatric Annals, 2005, 34, 62-68.	0.8	9
49	Impact of Cethromycin (ABT-773) Therapy on Microbiological, Histologic, Immunologic, and Respiratory Indices in a Murine Model of Mycoplasma pneumoniae Lower Respiratory Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 2897-2904.	3.2	29
50	Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model. Antimicrobial Agents and Chemotherapy, 2004, 48, 1811-1822.	3.2	96
51	Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases. Clinical Infectious Diseases, 2004, 39, 192-198.	5.8	276
52	Respiratory Syncytial Virus Induces Pneumonia, Cytokine Response, Airway Obstruction, and Chronic Inflammatory Infiltrates Associated with Longâ€Term Airway Hyperresponsiveness in Mice. Journal of Infectious Diseases, 2004, 189, 1856-1865.	4.0	159
53	Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae -Induced Pneumonia. Antimicrobial Agents and Chemotherapy, 2003, 47, 1614-1620.	3.2	45
54	Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 2003, 52, 651-655.	3.0	43

#	Article	IF	Citations
55	Treatment of respiratory syncytial virus: antiviral therapies. Pediatric Infectious Disease Journal, 2003, 22, S89-S93.	2.0	19
56	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, S89-S93.	2.0	14
57	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of Dexamethasone in Severe Respiratory Syncytial Virus (RSV) Infection: Effects on RSV Quantity and Clinical Outcome. Journal of Infectious Diseases, 2002, 185, 1222-1228.	4.0	134
58	Clinical Chorioamnionitis, Elevated Cytokines, and Brain Injury in Term Infants. Pediatrics, 2002, 110, 673-680.	2.1	199
59	Mycoplasma pneumoniae Induces Chronic Respiratory Infection, Airway Hyperreactivity, and Pulmonary Inflammation: a Murine Model of Infection-Associated Chronic Reactive Airway Disease. Infection and Immunity, 2002, 70, 649-654.	2.2	105
60	Role of chemokines in respiratory syncytial virus disease. Pediatric Infectious Disease Journal, 2002, 21, 454-456.	2.0	23
61	Elevated Cytokine and Chemokine Levels and Prolonged Pulmonary Airflow Resistance in a Murine Mycoplasma pneumoniaePneumonia Model: a Microbiologic, Histologic, Immunologic, and Respiratory Plethysmographic Profile. Infection and Immunity, 2001, 69, 3869-3876.	2.2	92
62	Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrobial Agents and Chemotherapy, 2001, 45, 3092-3097.	3.2	38
63	Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatric Infectious Disease Journal, 2000, 19, 1-7.	2.0	21
64	Efficacy of Gatifloxacin in Experimental Escherichia coli Meningitis. Antimicrobial Agents and Chemotherapy, 1999, 43, 1805-1807.	3.2	18
65	Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. Journal of Antimicrobial Chemotherapy, 1999, 43, 811-816.	3.0	13
66	Fluoroquinolones in Paediatrics. Drugs, 1999, 58, 43-48.	10.9	25
67	Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatric Infectious Disease Journal, 1999, 18, 115-122.	2.0	239
68	Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrobial Agents and Chemotherapy, 1999, 43, 876-881.	3.2	81
69	Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein. Journal of Infectious Diseases, 1998, 178, 1555-1561.	4.0	231
70	Pharmacodynamics of Gatifloxacin in Cerebrospinal Fluid in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrobial Agents and Chemotherapy, 1998, 42, 2650-2655.	3.2	72